Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipovax-Fg15-malaria
- Development stage
- Discontinued
- Lead developer
- Lipotek
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
Lipovax-Fg15-malaria is a preclinical-stage liposome-based vaccine developed by Lipotek Pty Ltd for the prevention of malaria. It is built on the Lipovax-Fg115 platform, which uses liposomes to deliver recombinant malaria antigens. The technology incorporates proprietary Fg115 (or Fg15) molecules that function as Toll-like receptor 5 (TLR5) agonists, facilitating the targeting and activation of dendritic cells to elicit a robust immune response. Antigens are attached to the liposome surface using histidine tags. Development of this candidate appears to have ceased, with no active reports identified since approximately 2020.
- Other names
- Lipotek malaria vaccine
02
Targets
TLR5
Beyond the preview
Go deeper on Lipovax-Fg15-malaria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipovax-Fg15-malaria.